Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Mesoblast (MSB) has submitted its Biologics Licence Application (BLA) to the U.S. Food and Drug Administration (US FDA) for Ryoncil
  • Ryoncil is the company’s lead cell therapy used to treat children with steroid-refractory acute graft versus host disease
  • Mesoblast requested the application be given Priority Review as there currently isn’t any FDA-approved treatments for children with this disease
  • If this goes well, Ryoncil is expected to be launched in the U.S. some time this year
  • Mesoblast is down a slight 0.67 per cent with shares trading at $2.98 each

Mesoblast (MSB) has submitted its Biologics Licence Application (BLA) to the United States Food and Drug Administration (US FDA) for Ryoncil.

Ryoncil (remestemcel-L) is Mesoblast’s lead allogeneic cell therapy which is used to treat children with steroid-refractory acute graft versus host disease (SR-aGVHD).

The regenerative medicine company filed the final module for the application with the FDA on January 31. It has requested Priority Review of the BLA by the FDA and, if approved, Ryoncil is expected to be launched in the U.S. this year.

“This is a major corporate milestone for Mesoblast,” CEO Dr Silviu Itescu said.

Acute GVHD occurs in about 50 per cent of patients who go through an allogenic bone marrow transplant.

In patients with the most severe form of the disease, mortality is as high as 90 per cent. Unfortunately however, there isn’t any FDA-approved treatments in the U.S. for children with SR-aGVHD.

Ryoncil has been used on 309 children with SR-aGVHD across three separate studies. It was used as a salvage therapy in an expanded access program in 241 children who failed institutional standard of care.

The lead drug candidate was also used as first-line therapy in Mesoblast’s Phase 3 trial in 55 children with SR-aGVHD, 89 per cent of whom has a severe form of the disease.

“We look forward to working closely with the FDA to potentially bring Ryoncil to market and providing our innovative biologic therapy to the many children with this life-threatening condition,” Dr Silviu added.

Mesoblast is down a slight 0.67 per cent with shares trading at $2.98 each at 12:11 pm AEDT.

MSB by the numbers
More From The Market Herald
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion (ASX:ALC) to raise $55m & acquire Silverlink

Alcidion (ALC) has announced plans to raise $55 million and buy patient software specialists, Silverlink PCS Software.
Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay

" Actinogen Medical (ASX:ACW) partners with Oxford University

Actinogen (ACW) has announced a collaboration with Oxford University researchers to investigate Xanamem and a condition called mild autonomous cortisol secretion (MACS).
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) soars on ‘positive’ Rett syndrome trial results

Neuren Pharmaceuticals’ (NEU) shares have soared following positive top-line results from a phase three study on Rett syndrome.

" Recce Pharmaceuticals (ASX:RCE) spikes amid trial update

Shares in Recce Pharmaceuticals (RCE) have spiked amid a positive update in the clinical trial for the treatment of burn wound infections.